Netakimab is a humanized IgG1 monoclonal antibody against IL-17a that was registered in Russia in spring 2020 for the treatment of psoriasis [22], ankylosing spondylitis [23] (ClinicalTrials.gov: NCT03447704), and psoriatic arthritis (ClinicalTrials.gov: NCT03598751). Here, IL17A is linked to ankylosing spondylitis.